Lifeboat Foundation

A team of researchers in the Faculty of Engineering of The University of Hong Kong (HKU) has developed a coin-sized system that can read weak electrochemical signals and can be used for personalized health monitoring and the measurement of such conditions as diabetes, cardiovascular diseases and mental health. The discovery was featured on the cover of Analytical Chemistry.

The PERfECT System—an acronym for Personalized Electronic Reader for Electrochemical Transistors—is the world’s smallest system of its kind, measuring 1.5 cm x 1.5 cm x 0.2 cm and weighing only 0.4 gram. It is easily wearable, for instance integrated with a smartwatch or as a patch, to allow for continuous monitoring of biosignals such as glucose levels and antibody concentrations in blood and even sweat.

Continue reading “Coin-sized wearable biosensing platform for digital health” »

Twenty people who were legally blind or visually impaired received a transplant of a cornea made from pig collagen. All of them had improved sight, including three who now have 20/20 vision after being legally blind.

PFAS are nicknamed “forever chemicals” because they last so long without breaking down. That’s made them pervasive in rainwater and soils.

Gene therapy pioneer — dr. katherine high, MD — president, therapeutics, askbio.

Dr. Katherine High, MD, is President, Therapeutics, at Asklepios BioPharmaceutical (AskBio — https://www.askbio.com/), where she is also member of the AskBio Board of Directors, and has responsibility for driving the strategic direction and execution of pre-clinical and clinical programs of the company.

Continue reading “Dr. Katherine High, MD — Gene Therapy Pioneer — President, Therapeutics, Asklepios BioPharmaceutical” »

There isn’t currently a Lyme disease vaccine on the U.S. market. Researchers are hoping to change that.

* FBL67: Jacob Ward – How AI Shapes Our Choices & Bad Habits * Future of funerals? Startup develops ‘holographic conversational video experience’ that allows mourners to have conversations with the dead * Police Used a Baby’s DNA to Investigate Its Father for a Crime.

* The Rise of the Worker Productivity Score * ‘Starbucks fired me for being three minutes late’ * Amazon starts selling private 5G, plants flag on pricing * We Need To Stop Cheerleading Change.

Continue reading “Futureseek Daily Link Review; 15 August 2022” »

Protein implant gave people who couldn’t see 20:20 vision.

A University of Minnesota Twin Cities-led team has found that electrical stimulation of the body combined with sound activates the brain’s somatosensory or “tactile” cortex, increasing the potential for using the technique to treat chronic pain and other sensory disorders. The researchers tested the non-invasive technique on animals and are planning clinical trials on humans in the near future.

The paper is published in the Journal of Neural Engineering, a highly regarded, peer-reviewed scientific journal for the interdisciplinary field of neural engineering.

During the experiments, the researchers played broadband sound while electrically stimulating different parts of the body in guinea pigs. They found that the combination of the two activated neurons in the brain’s somatosensory cortex, which is responsible for touch and pain sensations throughout the body.

The signaling protein, known as mTOR, is excessively active in many cancer cells and plays a key role in various diseases, such as diabetes, inflammation, and aging. Meanwhile, autophagy is well-known for its elaborately mediated regulation of activity by the mTOR protein in cells. Inhibiting this activity of the mTOR protein can increase autophagy and subsequently induce cancer cell death.

Professor Kim Se-yun’s research team conducted a study on developing an mTOR-inhibitory anticancer drug with a drug regeneration strategy based on effective binding technology that models physical interactions between compounds and target proteins using the three-dimensional protein structure.

Drug regeneration finds new indications for FDA-approved drugs or clinical drug groups previously proven safe. According to the researchers, this strategy can innovatively shorten the enormous time and investment in new drug development that traditionally takes more than 10 years.